Posts

Posted on

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

  • New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 
  • These data will further add to the already strong clinical data package for EVX-01
  • The trial remains on track for two-year clinical efficacy data readout in the second half of 2025

COPENHAGEN, Denmark, March 25, 2025 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data for its lead asset EVX-01 at a poster session at the American Association for Cancer Research (AACR) Annual Meeting taking place in Chicago April 25-30, 2025. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).

Evaxion will present new biomarker and immune data obtained from the ongoing phase 2 trial. These will further add to EVX-01’s already strong clinical data package.

“We are proud to be selected by the AACR’s scientific committee to present new data at this very renowned and important scientific meeting. This is a testament of the high scientific value of the EVX-01 clinical program, and we are excited to get the chance to present and discuss the data with a big audience in the field of melanoma research”, says Birgitte Rønø, Chief Scientific Officer of Evaxion.

The trial previously yielded strong interim one-year clinical data and remains on track for readout of two-year clinical data in the second half of 2025. Additionally, the trial has been extended with a third year, allowing for a more comprehensive assessment of the full potential of EVX-01.

AACR presentation details:

Abstract title:        T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab
Abstract#:        4538
Poster#:        9
Session (category):        Immune responses to therapies including chemotherapy and radiotherapy (Clinical research)
Location:        Poster section 28
Date/Time:        April 29, 2025, at 9am-12pm CST/16-19 CET                 
Presenter:         Mads Lausen Nielsen, PhD, Project Manager at Evaxion

The phase 2 trial investigates EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About EVX-01

EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. It is Evaxion’s lead clinical asset.

EVX-01 is designed with our AI-Immunology™ platform and is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumors.

In clinical trials, EVX-01 has demonstrated 69% and 67% Overall Response Rates in patients with advanced melanoma. Further, significant correlations between clinical responses and AI-Immunology™ predictions have been observed, underlining the predictive power of the platform.

Contact information 
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96

[email protected] 

About EVAXION

Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geo-political and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 



Posted on

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile

New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers

VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the acceptance of six abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held April 24-30, 2025 in Chicago, IL.

“As our wholly-owned pipeline continues to progress, we are excited to share updates at AACR on our novel multifunctional therapeutics addressing difficult-to-treat cancers,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “Among these, we are excited to share updates on ZW209, our DLL3-targeting trispecific T cell engager incorporating co-stimulation, which is on track for IND submission in 1H-2026, and ZW327, our Ly6E-targeting antibody-drug conjugate incorporating our proprietary topoisomerase 1 inhibitor payload, ZD06519. These preclinical findings demonstrate how our therapeutic approaches have the potential to improve outcomes for patients with currently limited treatment options.”

Poster Presentation Details

T cell Engagers:

Title: ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin expressing cancers
Abstract: 3503
Session Category: Immunology
Session Title: T Cell Engagers

ZW171, a mesothelin (MSLN)-targeting T cell engager, currently in global Phase 1 clinical studies, shows promising preclinical activity in an expanded range of MSLN-positive tumor models including patient derived organoid and/or xenograft models of ovarian, pancreatic, and non-small cell lung cancer. These new findings expand our understanding of ZW171’s differentiated profile and application to treat cancer models, further supporting our active clinical program’s goal of helping patients with multiple types of difficult-to-treat cancers.

Title: ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Abstract: 7318
Session Category: Immunology
Session Title: T Cell Engagers and Novel Antibody-Based Therapies

ZW209, a trispecific T cell engager designed to optimally co-engage CD3 and CD28 on T cells and DLL3 on tumor cells, demonstrates potent and differentiated anti-tumor activity in multiple models of small cell lung cancer relative to benchmark DLL3 targeting T cell engagers. ZW209 also displays a favorable pharmacokinetics and safety profile in non-human primates following repeat dosing supporting further development.

Antibody-Drug Conjugates:

Title: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
Abstract: 2874
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 2

ZW327, a potential first-in-class ADC targeting Ly6E, an antigen overexpressed in numerous tumor types including breast, lung, and digestive tract cancers, demonstrates promising preclinical activity, highlighting its potential as an innovative therapeutic approach. Utilization of a superior Ly6E binding and internalizing antibody with a proprietary topoisomerase 1 inhibitor payload, ZD06519, lends ZW327 a highly differentiated profile, with pronounced in vitro cytotoxicity against a panel of tumor cell line models, single administration tumor regression in multiple xenograft models, and a well-tolerated profile in species cross reactive preclinical toxicology.

Title: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7
Abstract: 1565
Session Category:  Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 1

Protein Tyrosine Kinase 7 (PTK7) over expression across multiple tumor types including breast, digestive tract, and lung cancers, makes it an attractive target for ADCs. To enable optimal targeting, and overcome limitations of prior PTK7 ADCs, we have identified a lead biparatopic antibody displaying improved binding and internalization relative to that achieved with monospecific PTK7 antibodies. Relative to cofetuzumab pelidotin, a prior clinical stage PTK7 ADC, the lead PTK7 biparatopic antibody evaluated as an ADC utilizing Zymeworks’ proprietary topoisomerase 1 inhibitor payload, ZD06519, demonstrates increased efficacy in lung cancer xenograft models.

Zymeworks scientists are coauthors on two additional presentations leveraging technologies to aid further in design and characterizations of ADCs:

Title: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection
Abstract: 1230
Session Category: Tumor Biology
Session Title: 3D Models and Bioprinting

Title: In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Abstract: 5482
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Discovery Assay Technologies

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ preclinical pipeline; the potential therapeutic effects of and commercial potential of zanidatamab and Zymeworks’ other product candidates; anticipated IND submissions and the timing thereof; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; anticipated preclinical and clinical data presentations; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “on track”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for its year ended December 31, 2024 (a copy of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
[email protected]   

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
[email protected]



Posted on

NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market

— Anticipated Listing March 26, Nasdaq Global Market: Symbol NTHI —

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (“NeOnc” or the “Company,” to be listed on the NASDAQ Global Market under the symbol: NTHI), a clinical-stage medical biotechnology company, today announced that its registration statement on Form S-1, as filed with the Securities and Exchange Commission (“SEC”), relating to a proposed public direct listing of its common stock, has been declared effective by the SEC. The Company anticipates that its common stock will begin trading on the Nasdaq Global Market under ticker symbol “NTHI” on March 26, 2025.

A copy of the prospectus related to the registration statement may be obtained by visiting EDGAR on the SEC website or via the investor relations page of NeOnc’s website at neonctech.com.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NeOnc Technologies, Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier.

The Company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.

The Company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit neonctech.com.

Important Cautions Regarding Forward Looking Statements

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding our expectations, possible or assumed future actions, business strategies, events, or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate,” or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results.

The Company cautions that statements and assumptions made in this news release constitute forward-looking statements without guaranteeing future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter, or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events, or otherwise, except as required by law.

Company Contact:

Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
[email protected]

Investor Relations:

Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
[email protected]
[email protected]



Posted on

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 (“AACR 2025”) in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago.

Invited speaker presentation details

Title: ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels
Session: New Drugs on the Horizon: Part 1
Session Date: Sunday, April 27, 2025
Session Time: 1:00 pm to 2:30 pm CDT
Presenter: Adam J. Pelzek, Ph.D., Associate Director, Abpro
Abstract & Data: Embargoed until time of presentation
   

About ABP-102/CT-P72

ABP-102/CT-P72 an investigational HER2 x CD3 bispecific T-cell engager designed using Abpro’s proprietary DiversImmune® platform to selectively target HER2-overexpressing tumor cells while reducing activity in HER2-low expressing normal tissues. Its tetravalent IgG1-[L]-scFv format enables bivalent HER2 binding with functionally monovalent CD3 engagement and is designed to optimize tumor selectivity and reduce cytokine-related toxicity. Abpro has an exclusive collaboration with Celltrion, a leading South Korean biotechnology company ranked among the world’s top 25 by market capitalization, to advance ABP-102/CT-P72 in development for the treatment of HER2+ breast, gastric, pancreatic, colorectal, and other cancers.

About Abpro

Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using Abpro’s proprietary DiversImmune® platform. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.co.



Abpro Contacts
Company: [email protected]
Investors: [email protected]
Media: [email protected]

Posted on

Kulicke & Soffa Introduces New Vertical Wire Solutions to Expand Market Leadership

PR Newswire

Elevating Memory Density with ATPremier MEM PLUS™


SINGAPORE
, March 25, 2025 /PRNewswire/ — Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa”, “K&S”, “we” or the “Company”) announced the launch of ATPremier MEM PLUS, serving high-volume memory applications.

The innovative ATPremier MEM PLUS™ is a cutting-edge wafer level packaging solution, deploying innovative vertical wire technology to address emerging advanced memory applications within today’s fast-paced semiconductor market. Engineered for high-volume, at-the-edge AI applications, K&S’ vertical wire technology has broken barriers to enable a new level of transistor-dense DRAM and NAND assembly.

The Company anticipates advanced process capabilities, such as ProVertical and ProCascade Loop, to enable emerging memory applications as well as high-density applications in high-volume semiconductor markets outside of the memory market.

At-the-edge AI applications are demanding unprecedented advancements in memory technology and are anticipated to grow above a 25% compound annual growth rate over the coming five years. Larger capacities, higher performance, greater power efficiency, and more compact formfactor are increasingly essential, given that the historic approach of driving package density through transistor shrink continues to be prohibitively expensive for most high-volume semiconductor applications.

This ongoing dynamic has created the need for increasingly complex advanced semiconductor packaging solutions, and K&S’ ATPremier MEM PLUS™ vertical wire solution and APTURA™ Fluxless Thermo-Compression (FTC) solution are both extremely well positioned to directly support future at-the-edge AI, memory and high computing needs.

The ATPremier platform is built to support advanced assembly requirements and provides an alternative to traditional copper pillar technology by removing the limitations of two-dimensional packaging. With capabilities to support next-generation memory devices, including in consumer mobile, this novel technology is enabling high-density advanced packaging without compromise. ATPremier reduces complexity, costs, and addresses the increasingly advanced needs of the high-volume semiconductor market.

ATPremier MEM PLUS™ delivers cutting-edge, memory-specific wafer-level packaging capabilities, empowering customers to stay ahead in the intensely competitive memory landscape. Key features include:

  • Response Based Processes

    Technologies which are proprietary to K&S, including ProVertical and ProCascade Loop, would meet the precision wire bonding requirements of vertical and cascade wire interconnects, thereby ensuring optimal performance for memory applications.
  • Advanced Optical System and Inspection Features

    Equipped with state-of-the-art optical systems and yield-enhancing inspection tools, safeguarding product quality at every stage.
  • Factory Automation Integration

    With the capability to integrate Auto Wafer Handlers or EFEM systems, ATPremier MEM PLUS supports seamless factory automation, improving efficiency and throughput in high-volume environments.

“By addressing critical challenges in Memory capability, the ATPremier MEM PLUS™ technology demonstrates a leap forward in efficiency and performance, offering our customers new opportunities to enhance the speed, capacity, and energy efficiency of memory products. This vision extends far beyond its initial use in DRAM. With inherent flexibility and scalability, the solution is positioned to deliver significant impact across broader IC applications, marking a future of high-performance devices at optimized costs,” said Ivy Qin, Kulicke & Soffa’s Vice President and General Manager of Ball Bonding.


Asterion®– PW

– another revolutionary K&S solution for Power Semiconductor Applications

K&S has separately announced the concurrent launch of Asterion®-PW, extending its leadership in power device applications with a fast and precise ultrasonic pin welding solution. This advanced solution sets a new standard for pin interconnect capability – redefining efficiency, precision, and reliability.


Visit K&S at SEMICON China 2025

Together with K&S’ broad portfolio of solutions, the ATPremier MEM PLUS™ and Asterion®– PW will debut at the SEMICON China Trade Show in Shanghai, from March 26 through March 28, 2025, at Hall N3 Booth #3431. 

About Kulicke & Soffa

Founded in 1951, Kulicke and Soffa Industries, Inc. specializes in developing cutting-edge semiconductor and electronics assembly solutions enabling a smarter and more sustainable future. Our ever-growing range of products and services supports growth and facilitates technology transitions across large-scale markets, such as advanced display, automotive, communications, compute, consumer, data storage, energy storage and industrial.

Contacts

Kulicke & Soffa

Marilyn Sim

Public Relations
+65-6880 9309
[email protected]

Kulicke & Soffa
Joseph Elgindy
Investor Relations
+1-215-784-7500
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/kulicke–soffa-introduces-new-vertical-wire-solutions-to-expand-market-leadership-302411090.html

SOURCE Kulicke & Soffa Industries, Inc.

Posted on

Kulicke & Soffa Introduces Asterion®-PW for Power Semiconductor Applications

PR Newswire

Redefining Pin Interconnect Technology with Sonotrode™


SINGAPORE
, March 25, 2025 /PRNewswire/ — Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa”, “K&S”, “we” or the “Company”) announced the launch of Asterion-PW, extending its leadership in power device applications with a fast and precise ultrasonic pin welding solution. This advanced solution sets a new standard for pin interconnect capability – redefining efficiency, precision, and reliability.

Power module devices currently deployed in renewable energy, automotive, and railroad applications are increasingly reliant on pin-based interconnects for critical power storage, management and delivery requirements. The Power module market is one of the fastest growing semiconductor markets – anticipated to support a 12% compound annual growth rate through 2029.

The Asterion-PW leverages market leading ultrasonic technology which is replacing traditional soldering in crucial applications due to accuracy and productivity improvements. Additionally, due to the elimination of flux and solder paste, the Sonotrode ultrasonic capability provides clear environmental benefits. The Asterion-PW platform also provides unparalleled speed and precision enabling higher throughput and superior quality:          

  • Unmatched Speed and Precision: With a high-resolution linear motor positioning system and innovative, patent-pending Sonotrode design, the Asterion®-PW achieves fine precision Pin placement repeatability.
  • Enhanced Productivity: An integrated high speed bulk pin feeder system and optional material handling system equipped with an advanced cleaning station ensure smooth operation. The cleaning system effectively removes contaminants before encapsulation, improving product quality.
  • Superior Cost of Ownership: The durable Sonotrode boasts one of the longest operational lifespans currently known in the industry, delivering less frequent change overs, outstanding reliability and cost efficiency.

“Precision drives innovation, and innovation transforms possibilities into realities. The Asterion®-PW for Power module applications is where innovative technology meets performance and cost of ownership benefits, redefining the future of manufacturing,” said Chan Pin Chong, Kulicke & Soffa’s Executive Vice President and General Manager of Products and Solutions.


ATPremier MEM PLUS™

– new K&S Vertical Wire solutions to serve high-volume memory

K&S has separately announced the concurrent launch of ATPremier MEM PLUS™, a cutting-edge wafer level packaging solution, which deploys innovative Vertical Wire technology positioned to support emerging advanced memory applications.


Visit K&S at SEMICON China 2025

Together with K&S’ broad portfolio of solutions, the Asterion®-PW andATPremier MEM PLUS™ will debut at the SEMICON China Trade Show in Shanghai, from March 26 through March 28, 2025, at Hall N3 Booth #3431. 

About Kulicke & Soffa

Founded in 1951, Kulicke and Soffa Industries, Inc. specializes in developing cutting-edge semiconductor and electronics assembly solutions enabling a smarter and more sustainable future. Our ever-growing range of products and services supports growth and facilitates technology transitions across large-scale markets, such as advanced display, automotive, communications, compute, consumer, data storage, energy storage and industrial.

Contacts

Kulicke & Soffa

Marilyn Sim

Public Relations
+65-6880 9309
[email protected]

Kulicke & Soffa
Joseph Elgindy
Investor Relations
+1-215-784-7500
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/kulicke–soffa-introduces-asterion-pw-for-power-semiconductor-applications-302411095.html

SOURCE Kulicke & Soffa Industries, Inc.

Posted on

Health in Tech Expands Access to Virtual Care Through Collaboration with DialCare

PR Newswire


STUART, Fla.
, March 25, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, is pleased to announce a strategic collaboration with DialCare, a leading provider of telehealth and virtual care solutions. The collaboration aims to enhance access to quality, affordable healthcare by integrating DialCare’s virtual primary care and behavioral health services into Health In Tech’s dynamic suite of self-funded health plan offerings.

Through this collaboration, Health In Tech will integrate DialCare’s services—including virtual primary care, therapy, and psychiatry—into its product offerings, members across the U.S. will benefit from streamlined, on-demand access to licensed providers via phone or video consultations.

“We’re proud to partner with DialCare to bring their trusted virtual care solutions into the hands of our members,” said Tim Johnson, CEO of Health In Tech. “Through this integration, employer groups with 10 or more lives can offer their employees convenient, affordable access to DialCare’s telemedicine services—all seamlessly quoted and managed through our eDIYBS technology. This collaboration aligns perfectly with our mission to deliver smarter, more accessible healthcare solutions for diverse populations.”

Members will benefit from access to licensed physicians, therapists, and psychiatric providers through DialCare’s mobile app and web platform, helping address both physical and mental health needs with convenience and care.

Together, Health In Tech and DialCare are redefining how care is delivered: patient-centric, technology-enabled, and focused on scalable, sustainable outcomes for employers and employees alike.

Use of Forward
–
Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.

About Health In Tech

Health In Tech (Nasdaq: “HIT”) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com.

About DialCare

DialCare is an innovative industry leader committed to providing affordable access to virtual care to help people improve their overall health and well-being. Across a robust suite of virtual health services, DialCare offers seven comprehensive, high-demand telehealth solutions, including a Physician Access program that provides 24/7/365 access to non-emergency care from a national network of U.S.-based, fully credentialed physicians and virtual primary care for long-term care of chronic conditions with dedicated physicians; a Mental Wellness program that provides virtual counseling and psychiatry with licensed mental health professionals for mental and behavioral health care; a Teledentistry program for 24/7/365 access to consultations with licensed dentists via video or phone chat; and a Virtual Vet program that provides 24/7/365 access to guidance and information from licensed veterinary professionals. DialCare is available nationally to consumers and organizations of any size or industry. DialCare’s virtual care solutions are available as standalone products or as part of a bundled offering. For more information on DialCare, please visit DialCare.com.

Investor Contact

Investor Relations:
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-expands-access-to-virtual-care-through-collaboration-with-dialcare-302411074.html

SOURCE Health In Tech

Posted on

CGI expands its presence in Québec City with the acquisition of Momentum Technologies

PR Newswire

Stock Market Symbols

GIB.A (TSX)

GIB (NYSE)

cgi.com/newsroom 


Acquisition deepens CGI’s data and business intelligence capabilities 

MONTRÉAL, March 25, 2025 /PRNewswire/ – CGI (TSX: GIB.A) (NYSE: GIB), one of the largest independent IT and business consulting services firms in the world, today announced the acquisition of Momentum Technologies, a Québec City based IT consulting services company, specializing in data analytics and business intelligence.

More than 250 highly skilled consultants and professionals will join CGI, deepening the company’s local presence and capacity to serve clients across the public sector and several commercial industries such as health and insurance.

“On behalf of CGI, we extend a warm welcome to the talented professionals from Momentum Technologies,” says Michael Godin, President of CGI’s operations in Canada. “Our organizations share similar values, expertise and a steadfast commitment to delivering exceptional services, aimed at driving tangible business outcomes for our clients. This marks the beginning of an exciting journey, where our combined strengths will unlock new opportunities to partner with our clients.”

“With this acquisition, we are further strengthening our presence in Québec City,” says Jalil El Mejjad, Senior Vice-President, Québec City, CGI. “Momentum Technologies has built an impressive reputation in this market for delivering high-quality services. This is also a natural evolution of our historically strong collaborations with Momentum Technologies over the years. By blending our expertise, we are enhancing our ability to serve our clients with an even broader range of AI capabilities to provide deeper insights and stronger analytics that enable clients to drive smarter decision-making.”

“Momentum Technologies has always been driven by a commitment to excellence, innovation and strong client relationships,” says Mohamed Guetat, President, Momentum Technologies. “Joining forces with CGI is an exciting chapter that aligns with our culture, values and vision for the future. As part of a larger organization with extensive resources and global reach, we will be able to provide even greater opportunities for our talented professionals, and enhanced solutions for our clients.”

Founded in 2003, Momentum Technologies is recognized as a leading local provider of innovative solutions that drive digital transformation and operational efficiency for businesses across various industries, including public sector. The company also specializes in managed services, cloud computing, and enterprise software development, empowering organizations with scalable, secure, and customized technology solutions.

About CGI
Founded in 1976, CGI is among the largest independent IT and business consulting services firms in the world. With 91,000 consultants and professionals across the globe, CGI delivers an end-to-end portfolio of capabilities, from strategic IT and business consulting to systems integration, managed IT and business process services and intellectual property solutions. CGI works with clients through a local relationship model complemented by a global delivery network that helps clients digitally transform their organizations and accelerate results. CGI Fiscal 2024 reported revenue is CA$14.68 billion and CGI shares are listed on the TSX (GIB.A) and the NYSE (GIB). Learn more at cgi.com.

Cision View original content:https://www.prnewswire.com/news-releases/cgi-expands-its-presence-in-quebec-city-with-the-acquisition-of-momentum-technologies-302411221.html

SOURCE CGI Inc.

Posted on

Cadence Bank Announces First Quarter 2025 Earnings Webcast Schedule

PR Newswire


HOUSTON and TUPELO, Miss., March 25, 2025 /PRNewswire/ — Cadence Bank (NYSE: CADE) will release its first quarter 2025 earnings on Monday, Apr. 21, 2025, after the close of the financial markets. It will also hold its earnings webcast on Tuesday, Apr. 22, 2025, at 10 a.m. CT.

The webcast will be live coverage of management’s conference call with analysts and can be found by visiting: https://ir.cadencebank.com/events. This will be an interactive session between management and analysts; others may listen to the live broadcast as it happens. The conference call will also be available in archived format at the same web address.

About Cadence Bank

Cadence Bank (NYSE: CADE) is a $50 billion regional financial services company committed to helping people, companies and communities prosper. With more than 350 locations spanning the South and Texas, Cadence offers comprehensive banking, investment, trust and mortgage products and services to meet the needs of individuals, businesses and corporations. Accolades include being recognized as one of the nation’s best employers by Forbes and U.S. News & World Report and a 2025 America’s Best Banks by Forbes. Cadence maintains dual headquarters in Houston, Texas, and Tupelo, Mississippi, and has dutifully served customers for nearly 150 years. Learn more at www.cadencebank.com. Cadence Bank, Member FDIC. Equal Housing Lender.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cadence-bank-announces-first-quarter-2025-earnings-webcast-schedule-302411047.html

SOURCE Cadence Bank

Posted on

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

PR Newswire

— Abstract accepted for late-breaking poster presentation –

— EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers —

— On-track to file an Investigational New Drug (IND) application in 2026 –


BOSTON
, March 25, 2025 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois.

EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4. Elevation Oncology designed EO-1022, leveraging the advanced site-specific conjugation technology platform licensed from Synaffix B.V. Elevation Oncology is developing EO-1022 for the treatment of solid tumors that express HER3, including breast cancer and non-small cell lung cancer, and expects to file an IND application in 2026.

“We are eager to share the first preclinical data for EO-1022 at the AACR Annual Meeting,” said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. “With EO-1022, we are combining the most advanced site-specific conjugation technology platform with the clinically validated MMAE payload, which is widely used across ADC programs but has yet to be introduced into a HER3-targeting ADC in the clinic. We believe this unique combination will enable us to provide a new treatment option to patients with HER3-expressing solid tumors, including those who are refractory to other HER3-targeting agents in development. We look forward to advancing EO-1022 into clinical development next year.”

Details of the poster presentation at AACR 2025 are as follows:

Title: Preclinical discovery and characterization of EO-1022, a site-specific glycan-conjugated anti-HER3 vc-MMAE ADC for treating solid tumors

  • Abstract Presentation Number: LB004
  • Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 1
  • Session Date and Time:
    Sunday, April 27, from 2 p.m. to 5 p.m. CT (3 p.m. to 6 p.m. ET)
  • Location: Poster Section 50

The late-breaking abstract will become available on the AACR website beginning at 12:00 noon CT (1:00 p.m. ET) on April 25, 2025, and published in an online-only supplement to Cancer Research.

About EO-1022

Elevation Oncology is developing EO-1022, a potentially differentiated HER3 ADC for the treatment of HER3-expressing solid tumors, including breast cancer and non-small cell lung cancer. EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 antibody, site-specifically conjugated at glycan to the MMAE payload with a DAR of 4. It leverages seribantumab’s desirable internalization properties and advanced site-specific ADC technology which makes possible the use of the potent cytotoxic MMAE payload. Elevation Oncology expects to file an IND application in 2026.

About Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our ADC expertise to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors. EO-1022 is currently progressing through preclinical development, with an investigational new drug (IND) application expected in 2026. For more information, visit www.ElevationOncology.com.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of preclinical results, potential benefits of product candidates, potential market opportunities for product candidates and the ability of product candidates to treat their targeted indications. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “will,” “would,” and other words and terms of similar meaning. Although Elevation Oncology believes that the expectations reflected in such forward-looking statements are reasonable, Elevation Oncology cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Elevation Oncology’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Elevation Oncology’s ability to advance its product candidates, the timing and results of preclinical studies and clinical trials, approvals and commercialization of product candidates, the receipt and timing of potential regulatory designations, Elevation Oncology’s ability to fund development activities and achieve development goals, Elevation Oncology’s ability to protect intellectual property, Elevation Oncology’s ability to establish and maintain collaborations with third parties, and other risks and uncertainties described under the heading “Risk Factors” in documents Elevation Oncology files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Elevation Oncology undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Elevation Oncology Investor and Media Contact

Gracie Tong

Senior Director, Investor Relations and Corporate Communications
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-preclinical-data-for-eo-1022-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025-302407842.html

SOURCE Elevation Oncology